Primary hypertension
2 papers1 finding
- Human trial1
- Humans1
Associations
1Semaglutide
downin humans1
1 study
Semaglutide
downin humans1
Semaglutide lowers the risk of primary hypertension in humans (HRs ranging 0.69-0.84, all p<0.05).
“Primary hypertension risk decreased with semaglutide versus all comparators (HRs ranging 0.69-0.84, all p<0.05)”
Humanstwo years
ENDO 2025 abstract22 Oct 2025
Trial sponsors
Company1 trialPhase 420,702 people
Company1 trialPhase 2304 people
University of Erlangen-Nürnberg Medical School
1 trialPhase 350 people
China Institute of Sport Science
1 trial1 person
Southern University of Science and Technology
1 trial1 person
Latest
7 in 12 monthsFrontiers in Medicine
Trajectory-based associations between a structured acupressure protocol, blood pressure variability, and autonomic balance in patients with primary hypertension
Non-randomised trial in peopleHypertension
American Journal of Preventive Cardiology
Study design, rationale, and baseline characteristics of ATTAIN-HYPERTENSION, a phase 3 trial of the oral GLP-1 receptor agonist orforglipron for hypertension
Trial protocolGLP-1 receptor agonists
Medicine
Association between serum zinc levels and new-onset hypertension: A 5-year retrospective cohort study
Cohort study of 47,843 peopleHypertension
Frontiers in Neurology
Cerebral microbleeds on susceptibility-weighted imaging, cognitive domains, and serum neurofilament light chain in adults with hypertension
Cross-sectional study of 173 peopleNfL
Frontiers in Medicine
Effects of Wuqinxi on blood pressure and lipids in hypertensive middle-aged and elderly adults: a meta-analysis
Meta-analysis of randomised trialsHypertension
AHA Scientific Sessions 2025 Abstract
Different Criteria of Prediabetes and Cardiovascular Risk and Mortality: A Prospective Cohort and Mendelian Randomization and Imaging Study in the UK Biobank
Cohort study of 278,697 peoplePrediabetes
ENDO 2025 Abstract
MON-684 Comparative Effectiveness and Safety of GLP-1 Receptor Agonist versus Traditional Anti-obesity Medications: A Real-world Evidence Study
Cohort study of 10,544 peopleGLP-1 receptor agonists